+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Treatment of Blastic-Phase CML Market by Treatment Type, Therapy Line, Mechanism Of Action, Route Of Administration, End User, Distribution Channel, Patient Age Group - Global Forecast to 2030- Product Image
Treatment of Blastic-Phase CML Market by Treatment Type, Therapy Line, Mechanism Of Action, Route Of Administration, End User, Distribution Channel, Patient Age Group - Global Forecast to 2030- Product Image
Sale

Treatment of Blastic-Phase CML Market by Treatment Type, Therapy Line, Mechanism Of Action, Route Of Administration, End User, Distribution Channel, Patient Age Group - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6085417
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Blastic-phase chronic myeloid leukemia (CML) represents one of the most challenging areas in hematologic oncology, as stakeholders seek innovative solutions to address rapid disease progression, drug resistance, and shifting policy environments. Senior decision-makers navigating this dynamic landscape require a comprehensive understanding of the evolving treatment paradigm and the implications of regulatory and market access factors.

Market Snapshot: Blastic-Phase CML Treatment Trends

The blastic-phase CML treatment market is experiencing significant transformation, reflecting a push toward precision medicine and advanced therapeutic options. Growth is propelled by the emergence of targeted small molecule inhibitors and supportive regulatory frameworks across leading regions. The market continues to see increased uptake of next-generation therapies as oncology providers and payers focus on optimizing patient outcomes and addressing high disease burden. The rising prevalence and complexity of cases demand adaptable commercial strategies and a nuanced appreciation of access drivers and barriers.

Scope & Segmentation

This report delivers a detailed analysis of the blastic-phase CML landscape, breaking down the market by therapy, mechanism of action, administration, and more. Senior leaders can align their strategy with targeted insights across:

  • Treatment Type: Combination therapies, monoclonal antibodies, and small molecule inhibitors are each covered for their roles in efficacy and regimen design.
  • Therapy Line: The report segments the landscape by first-line, second-line, and third-line and beyond therapies, highlighting how regimen selection shifts as resistance develops.
  • Mechanism Of Action: Analysis spans Bcr-Abl inhibitors, chemotherapy agents, and the emergence of immunomodulators as adjunct therapies.
  • Route Of Administration: Oral and intravenous options are compared in relation to disease severity and patient management considerations.
  • End User: Perspectives on utilization by hospitals, specialty clinics, and ambulatory surgical centers underscore shifts toward decentralized care and varying supportive needs.
  • Distribution Channel: Hospital, retail, and online pharmacy trends are explored regarding direct-to-patient delivery.
  • Patient Age Group: Segmentation covers both adults, who represent the main patient cohort, and pediatric cases requiring specialized protocols.
  • Geography: Americas, Europe/Middle East/Africa, and Asia-Pacific are each analyzed, including high-focus countries across North America, Europe, and Asia.
  • Company Landscape: The activities of leading firms such as Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Takeda Pharmaceutical, and others are profiled.

Key Takeaways for Senior Decision-Makers

  • Adoption of targeted small molecule inhibitors and immunomodulatory approaches is rewriting standards of care, supported by both clinical trial data and real-world experience.
  • Personalized therapy protocols are possible through advanced diagnostics, including next-generation sequencing and digital pathology, resulting in improved alignment of patient and treatment profiles.
  • Flexible dosing and administration routes facilitate better adherence and allow clinicians to tailor regimens based on disease complexity and healthcare setting.
  • Hospitals remain the main treatment centers, but specialty and ambulatory clinics are expanding service capacity for outpatient care, reflecting broader shifts in oncology delivery models.
  • Distribution trends indicate increasing role of online pharmacies and retail channels, especially for oral therapies, broadening accessibility pathways for patients.
  • Pediatric blastic-phase CML cases, while less common, require distinct dosing and monitoring, driving niche innovation within the therapy development pipeline.

Tariff Impact on Accessibility and Supply

Anticipated US tariff changes in 2025 are likely to increase production costs due to tariffs on pharmaceutical ingredients and excipients. Manufacturers may adjust supply chains by relocating or diversifying sourcing. This environment will pressure pricing negotiations, necessitate early payer engagement, and could lead to alternative distribution strategies. Strategic localization, for example through partnerships with US-based contract manufacturers, might offer tariff exemptions, and companies that adapt rapidly can optimize affordability and continuity.

Methodology & Data Sources

This analysis is grounded in comprehensive secondary research, including scientific literature, regulatory filings, and clinical trial registries. These sources were supplemented by primary research through in-depth interviews with leading hematologists, oncologists, health economists, and payer representatives. Findings were validated by an advisory panel of field experts, ensuring strong credibility and actionable insights.

Why This Report Matters

  • Provides strategic, actionable insights to inform commercial, product, and investment decisions within the blastic-phase CML treatment market.
  • Enables market access teams and product strategists to anticipate shifts in regulatory, reimbursement, and supply chain dynamics that will influence therapy adoption and profitability.
  • Arms C-suite leaders with the comprehensive, validated intelligence needed to optimize resource allocation and gain competitive advantage within an evolving therapeutic landscape.

Conclusion

The blastic-phase CML market continues to evolve, shaped by innovative therapies, policy changes, and a growing emphasis on precision medicine and patient-centric models. Equipping senior stakeholders with actionable intelligence ensures readiness to capture emerging opportunities and drive improved patient outcomes.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Treatment of Blastic-Phase CML Market, by Treatment Type
8.1. Introduction
8.2. Combination Therapies
8.3. Monoclonal Antibodies
8.4. Small Molecule Inhibitors
9. Treatment of Blastic-Phase CML Market, by Therapy Line
9.1. Introduction
9.2. First Line
9.3. Second Line
9.4. Third Line And Beyond
10. Treatment of Blastic-Phase CML Market, by Mechanism Of Action
10.1. Introduction
10.2. Bcr-Abl Inhibitors
10.3. Chemotherapy Agents
10.4. Immunomodulators
11. Treatment of Blastic-Phase CML Market, by Route Of Administration
11.1. Introduction
11.2. Intravenous
11.3. Oral
12. Treatment of Blastic-Phase CML Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Hospitals
12.4. Specialty Clinics
13. Treatment of Blastic-Phase CML Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Online Pharmacy
13.4. Retail Pharmacy
14. Treatment of Blastic-Phase CML Market, by Patient Age Group
14.1. Introduction
14.2. Adults
14.3. Pediatrics
15. Americas Treatment of Blastic-Phase CML Market
15.1. Introduction
15.2. United States
15.3. Canada
15.4. Mexico
15.5. Brazil
15.6. Argentina
16. Europe, Middle East & Africa Treatment of Blastic-Phase CML Market
16.1. Introduction
16.2. United Kingdom
16.3. Germany
16.4. France
16.5. Russia
16.6. Italy
16.7. Spain
16.8. United Arab Emirates
16.9. Saudi Arabia
16.10. South Africa
16.11. Denmark
16.12. Netherlands
16.13. Qatar
16.14. Finland
16.15. Sweden
16.16. Nigeria
16.17. Egypt
16.18. Turkey
16.19. Israel
16.20. Norway
16.21. Poland
16.22. Switzerland
17. Asia-Pacific Treatment of Blastic-Phase CML Market
17.1. Introduction
17.2. China
17.3. India
17.4. Japan
17.5. Australia
17.6. South Korea
17.7. Indonesia
17.8. Thailand
17.9. Philippines
17.10. Malaysia
17.11. Singapore
17.12. Vietnam
17.13. Taiwan
18. Competitive Landscape
18.1. Market Share Analysis, 2024
18.2. FPNV Positioning Matrix, 2024
18.3. Competitive Analysis
18.3.1. Novartis AG
18.3.2. Bristol-Myers Squibb Company
18.3.3. Pfizer Inc.
18.3.4. Takeda Pharmaceutical Company Limited
18.3.5. Sun Pharmaceutical Industries Limited
18.3.6. Teva Pharmaceutical Industries Limited
18.3.7. Viatris Inc.
18.3.8. Sandoz International GmbH
18.3.9. Lupin Limited
18.3.10. Hikma Pharmaceuticals PLC
19. ResearchAI
20. ResearchStatistics
21. ResearchContacts
22. ResearchArticles
23. Appendix
List of Figures
FIGURE 1. TREATMENT OF BLASTIC-PHASE CML MARKET MULTI-CURRENCY
FIGURE 2. TREATMENT OF BLASTIC-PHASE CML MARKET MULTI-LANGUAGE
FIGURE 3. TREATMENT OF BLASTIC-PHASE CML MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 20. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. TREATMENT OF BLASTIC-PHASE CML MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. TREATMENT OF BLASTIC-PHASE CML MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TREATMENT OF BLASTIC-PHASE CML MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY BCR-ABL INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 48. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 49. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 50. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 51. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 53. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 54. CANADA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 55. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 56. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 57. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 58. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 60. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 61. MEXICO TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 68. BRAZIL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 83. EUROPE, MIDDLE EAST & AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 84. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 85. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 90. UNITED KINGDOM TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 91. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 92. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 93. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 94. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 97. GERMANY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 98. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 99. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 100. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 101. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 104. FRANCE TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 105. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 106. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. RUSSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 112. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 113. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 114. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 115. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. ITALY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 119. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 120. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 121. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 122. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 125. SPAIN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 126. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 127. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. UNITED ARAB EMIRATES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 133. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 134. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 139. SAUDI ARABIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 140. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 141. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 146. SOUTH AFRICA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 147. DENMARK TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 148. DENMARK TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 149. DENMARK TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 150. DENMARK TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. DENMARK TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. DENMARK TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. DENMARK TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 154. NETHERLANDS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 155. NETHERLANDS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 160. NETHERLANDS TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 161. QATAR TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 162. QATAR TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 163. QATAR TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 164. QATAR TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. QATAR TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 166. QATAR TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 167. QATAR TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 168. FINLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 169. FINLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 170. FINLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 171. FINLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. FINLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. FINLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. FINLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 181. SWEDEN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 182. NIGERIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 183. NIGERIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 188. NIGERIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 189. EGYPT TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 190. EGYPT TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 191. EGYPT TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 192. EGYPT TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. EGYPT TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. EGYPT TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. EGYPT TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 196. TURKEY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 197. TURKEY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 198. TURKEY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 199. TURKEY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. TURKEY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 201. TURKEY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 202. TURKEY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 203. ISRAEL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 204. ISRAEL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 209. ISRAEL TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 210. NORWAY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 211. NORWAY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 212. NORWAY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 213. NORWAY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. NORWAY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 215. NORWAY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. NORWAY TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 217. POLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 218. POLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 219. POLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 220. POLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. POLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 222. POLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 223. POLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 230. SWITZERLAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 238. ASIA-PACIFIC TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 239. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 240. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 241. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 242. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 244. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 245. CHINA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 246. INDIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 247. INDIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 248. INDIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 249. INDIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. INDIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. INDIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. INDIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 253. JAPAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 254. JAPAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 255. JAPAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 256. JAPAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. JAPAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 258. JAPAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 259. JAPAN TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 266. AUSTRALIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 267. SOUTH KOREA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 273. SOUTH KOREA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 280. INDONESIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 281. THAILAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 282. THAILAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 283. THAILAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 284. THAILAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. THAILAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. THAILAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 287. THAILAND TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 288. PHILIPPINES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 289. PHILIPPINES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 290. PHILIPPINES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 294. PHILIPPINES TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY PATIENT AGE GROUP, 2018-2030 (USD MILLION)
TABLE 295. MALAYSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 296. MALAYSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY THERAPY LINE, 2018-2030 (USD MILLION)
TABLE 297. MALAYSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 298. MALAYSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 299. MALAYSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 300. MALAYSIA TREATMENT OF BLASTIC-PHASE CML MARKET SIZE, BY DIS

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Treatment of Blastic-Phase CML market report include:
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Limited
  • Viatris Inc.
  • Sandoz International GmbH
  • Lupin Limited
  • Hikma Pharmaceuticals PLC

Related Topics

Related Reports

Pharmaceuticals - Enterprise ICT - Product Image

Pharmaceuticals - Enterprise ICT

  • Report
  • 54 Pages
  • Global
From
Pharmaceuticals North America (NAFTA) Industry Guide 2019-2028 - Product Image

Pharmaceuticals North America (NAFTA) Industry Guide 2019-2028

  • Report
  • 286 Pages
  • North America
From
Asia-Pacific Pharmaceutical Industry Outlook 2023 - Product Image

Asia-Pacific Pharmaceutical Industry Outlook 2023

  • Report
  • 77 Pages
  • Asia Pacific
From
TIL Therapies Market Report and Forecast 2025-2034 - Product Image

TIL Therapies Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Clevecord Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Clevecord Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.